Daiichi Sankyo was on Monday forced to reveal a Y359.4bn ($3.84bn) loss on its acquisition of a controlling stake in Ranbaxy Laboratories, just over six months after the Japanese pharmaceuticals group took over the Indian generic drugmaker.

Daiichi Sankyo warned that a fall in value of the 64 per cent holding in Ranbaxy would mean its full-year profits would be lower than expected.